Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05808634 | Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. | PHASE1 | RECRUITING | 168 | — | — | Jul 14, 2023 | Sep 15, 2028 | Sep 25, 2025 | 9 | United States |
Phase 1 Part 1: Safety Profile of BA3182
Phase 1 Part 1: Safety Profile of BA3182
Phase 1 Part 2: Antitumor activity of BA3182
| Arm | Type | Description |
|---|---|---|
| BA3182 | EXPERIMENTAL | All Patients will receive BA3182 |
| Name | Type | Description |
|---|---|---|
| BA3182 | DRUG | Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM |
Inclusion Criteria: * Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma * Age ≥ 18 years * Adequate renal function * Adequate liver function * Adequate hematological function * Have an Eastern Cooperative Oncology Group (ECOG) performance status of...